Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling

Cancer Gene Ther. 2022 Dec;29(12):1988-2000. doi: 10.1038/s41417-022-00506-w. Epub 2022 Aug 1.

Abstract

Although androgen receptor (AR) can influence bladder cancer (BCa) initiation and progression, its impact on tumor immune escape remains unclear. Here, we found that targeting AR could enhance natural killer (NK) cell tumor-killing efficacy by decreasing PD-L1 expression. Both antiandrogen treatment and AR knockdown effectively reduced membrane PD-LI expression to facilitate NK cell-mediated BCa cell killing by downregulating circ_0001005. Mechanistically, AR upregulated circRNA circ_0001005 expression via the RNA-editing gene ADAR2. circ_0001005 competitively sponged the miRNA miR-200a-3p to promote PD-L1 expression. A preclinical BCa xenograft mouse model further confirmed this newly identified signaling using the small molecule circ_0001005-shRNA to improve NK cell killing of BCa tumor cells. Collectively, these results suggest that targeting the newly identified ADAR2/circ_0001005/miR-200a-3p/PD-L1 pathway to impact antitumor immunity may suppress progression and boost immunotherapeutic efficacy in BCa.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Deaminase / metabolism
  • Animals
  • B7-H1 Antigen / genetics
  • B7-H1 Antigen / metabolism
  • Cell Death
  • Cell Line, Tumor
  • Cell Proliferation
  • Humans
  • Killer Cells, Natural
  • Mice
  • MicroRNAs* / genetics
  • RNA-Binding Proteins / genetics
  • Receptors, Androgen* / genetics
  • Urinary Bladder Neoplasms* / genetics
  • Urinary Bladder Neoplasms* / pathology
  • Urinary Bladder Neoplasms* / therapy

Substances

  • Adenosine Deaminase
  • B7-H1 Antigen
  • MicroRNAs
  • Receptors, Androgen
  • RNA-Binding Proteins
  • ADARB1 protein, human
  • AR protein, human
  • MIRN200 microRNA, human